公众号 / 文章重症综合管理与镇静镇痛消化、代谢与肾脏急症

我们在ICU血糖控制起伏中的科学之旅

Our Scientific Journey through the Ups and Downs of Blood Glucose Control in the ICU.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论作者基于系列RCT认为,ICU患者应强烈推荐省略早期肠外营养,以减少血糖控制需求并让细胞管家系统在恢复中发挥作用(作者观点)。

本文叙述了作者团队长期探索应激性高血糖在危重症患者中是适应性还是适应不良的历程。早期三项RCT发现 tight glucose control 可降低 morbidity 和 mortality,但后续RCT未证实获益,大型NICE-SUGAR试验发现 tight glucose control 伴严重低血糖时死亡率增加。作者后续研究揭示早期肠外营养是混杂因素,早期-PN加重高血糖、抑制细胞损伤清除并妨碍恢复。在最大的TGC-fast RCT中,不使用早期-PN并以计算机算法避免严重低血糖的 tight glucose control 预防了肾和肝损伤,但效应量远小于早期RCT,且未影响死亡率。作者最终强烈推荐ICU患者省略早期-PN。

要点

  • 作者强烈推荐ICU患者省略早期肠外营养,以减少血糖控制需求并允许细胞管家系统在恢复中发挥进化选择的作用(作者观点)。
  • 早期三项RCT发现 tight glucose control 降低 morbidity 和 mortality,但后续RCT未证实获益。
  • NICE-SUGAR试验发现 tight glucose control 伴严重低血糖时死亡率增加。
  • 早期肠外营养是早期RCT的混杂因素,早期-PN加重高血糖、抑制细胞损伤清除并妨碍恢复。
  • TGC-fast RCT中,不使用早期-PN并以计算机算法避免严重低血糖的 tight glucose control 预防了肾和肝损伤,但效应量远小于早期RCT,未影响死亡率。

适用人群与场景

  • ICU患者

处置流程与药物剂量

  • 作者强烈推荐ICU患者省略早期肠外营养(early-PN),以减少血糖控制需求并允许细胞管家系统在恢复过程中发挥进化选择的作用。
  • 在TGC-fast RCT中,tight glucose control 使用计算机算法以避免严重低血糖。

研究设计与关键结果

  • 早期三项RCT发现 tight glucose control 降低 morbidity 和 mortality。
  • 后续多项RCT未证实 tight glucose control 的获益。
  • 大型NICE-SUGAR试验发现 tight glucose control 伴严重低血糖时死亡率增加。
  • 早期肠外营养是早期RCT的混杂因素,早期-PN加重高血糖、抑制细胞损伤清除并妨碍恢复。
  • TGC-fast RCT中,不使用早期-PN并以计算机算法避免严重低血糖的 tight glucose control 预防了肾和肝损伤,但效应量远小于早期RCT,未影响死亡率。

证据类型、等级与局限

  • 证据类型:叙述性综述(作者团队研究历程总结)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者强烈推荐ICU患者省略早期肠外营养,以减少血糖控制需求并允许细胞管家系统在恢复过程中发挥进化选择的作用。
  • 作者认为,在重症监护中,少即是多(less is more)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

This article tells the story of our long search for the answer to one question: Is stress hyperglycemia in critically ill patients adaptive or maladaptive? Our earlier work had suggested the lack of hepatic insulin effect and hyperglycemia as jointly predicting poor outcome. Therefore, we hypothesized that insulin infusion to reach normoglycemia, tight glucose control, improves outcome. In three randomized controlled trials (RCTs), we found morbidity and mortality benefit with tight glucose control. Moving from the bed to the bench, we attributed benefits to the prevention of glucose toxicity in cells taking up glucose in an insulin-independent, glucose concentration gradient-dependent manner, counteracted rather than synergized by insulin. Several subsequent RCTs did not confirm benefit, and the large Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation, or "NICE-SUGAR," trial found increased mortality with tight glucose control associated with severe hypoglycemia. Our subsequent clinical and mechanistic research revealed that early use of parenteral nutrition, the context of our initial RCTs, had been a confounder. Early parenteral nutrition (early-PN) aggravated hyperglycemia, suppressed vital cell damage removal, and hampered recovery. Therefore, in our next and largest "TGC-fast" RCT, we retested our hypothesis, without the use of early-PN and with a computer algorithm for tight glucose control that avoided severe hypoglycemia. In this trial, tight glucose control prevented kidney and liver damage, though with much smaller effect sizes than in our initial RCTs without affecting mortality. Our quest ends with the strong recommendation to omit early-PN for patients in the ICU, as this reduces need of blood glucose control and allows cellular housekeeping systems to play evolutionary selected roles in the recovery process. Once again, less is more in critical care.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Van den Berghe G, Vanhorebeek I, Langouche L, et al. Our Scientific Journey through the Ups and Downs of Blood Glucose Control in the ICU. Am J Respir Crit Care Med. 2024. PMID: 37991900. doi:10.1164/rccm.202309-1696SO

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。